Clinical trial · Interventional
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Lomustine Chemotherapy for Patients With Primary Recurrent Malignant Brain Tumours for Whom Lomustine Would be a Standard Therapy
NCT00503204CI-TRIAL-00002826completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor | Brain Neoplasm | ALIAS | 0.90 |
| Recurrent Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- Lomustine + Cediranib (AZD2171)
- interventionNames
- Drug: Cediranib
- Drug: Lomustine
Primary outcomes (1)
- measure
- Assess the safety and tolerability of cediranib in combination with oral lomustine and to confirm a dose for further studies with this combination.
- timeFrame
- Assessed at each visit
Secondary outcomes (1)
- measure
- Compare the pharmacokinetics of cediranib alone versus when in combination with lomustine as measured by minimum steady state plasma concentration (Css,min) steady-state plasma concentration
- timeFrame
- assessed 2 & 4 hours post dosing
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Primary recurrent malignant brain tumour for whom lomustine would be standard therapy - diagnosis \& stage * Patients received no more than 2 previous systemic chemotherapy regimes * Life Expectancy \> 12 weeks * Patients must be at least 3 months from the completion of cranial radiation therapy Exclusion Criteria: * History of poorly controlled high blood pressure * Recent major surgery prior to entry into the study
References
Publications (0)
Data not yet available
No reference posted for this study.